APAC Cancer Metabolism Based Therapeutics Market

The size of the Asia Pacific Cancer Metabolism Based Therapeutics market is predicted to register a promising CAGR between 2024 to 2029.

In the near future, limited alternatives for cancer metabolism targeted medicines could present prospective prospects for developing innovative cancer metabolism-based medications. Cancer metabolism is based on the principle that cancer cells modify glucose and glutamine metabolism to synthesize lipids, nucleotides, fatty acids, and proteins, which aids cancer cell proliferation. It inhibits the citric acid cycle, glucose, mitochondrial respiration, and glutamine consumption, among other metabolic pathways.

The prominent players operating in the Asia Pacific cancer metabolism-based therapies market are expected to enhance their strategic collaborations to expand their market presence and product offering, which is expected to drive market growth during the forecast period. The primary focus is on medications that inhibit or change the activity of key enzymes involved in lactate metabolism, the pentose phosphate pathway, lipid metabolism, amino acid metabolism, nucleotide metabolism, and the TCA cycle in cancer cells. Cancer medications are also being driven by several factors, including an increase in cancer incidence, the development of advanced therapies, and the introduction of biosimilars.

The market is further expected to be driven by novel drugs that are being precisely created to target inhibiting metabolic pathways and key enzymes involved in cancer cell metabolism. Reduced oxidative phosphorylation, aerobic glycolysis, and enhanced synthesis of biosynthetic intermediates required for cell growth and proliferation are just a few of the metabolic changes seen in cancer cells. Cancer metabolism treatments reconfigure nutrient acquisition and metabolic pathways to keep cells in a biosynthetic, bioenergetic, and redox balance. Extensive research is currently being carried out to see if certain enzymes in metabolic pathways might be used as therapeutic cancer targets. Mutations in oncogenes and cell signaling pathways are frequently responsible for changes in metabolic processes in cancer cells. However, now that specific enzymes within each metabolic pathway have been identified, it is expected that medications targeting these enzymes will have a high efficacy in treating cancer while having low side effects.

However, the high expense of new medication development, along with the risk of side effects associated with cancer therapeutic therapies, would put a halt to the market's growth.

This research report on the APAC Cancer Metabolism Based Therapeutics Market has been segmented & sub-segmented into the following categories:

By Therapy:

• Biological Drug Therapies  
• Targeted Drug Therapies  

By Drug Type:

• Enasidenib              
• CPI-613    
• Other Drugs      

By Indication:

• Melanoma              
• Myelodysplastic Syndrome (MDS)
• Acute Myeloid Leukemia (AML)    
• Metastatic Renal Cell Carcinoma    
• Others     

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Due to an increase in the number of cancer-affected people and increased awareness about various malignancies, Asia-Pacific is predicted to expand at the fastest CAGR. Because the number of cancer cases in developing countries like India and China is rising every year, there is a lot of growth in these markets. Experimental and conceptual advancements in this field have provided a better understanding of the role of metabolic pathways in cancer treatment over time. Because of the complexity of these pathways, progress has been slow in this area. However, the discovery that cancer cells' metabolic adaptations support their malignant qualities has led to the development of innovative cancer therapy techniques; targeted inhibition of altered metabolic pathways in cancer cells is a useful approach.

KEY MARKET PLAYERS:

Some of the prime manufacturers in the Asia-Pacific Cancer Metabolism Based Therapeutics are AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health.